MX2020013883A - Tratamientos oncológicos con agentes de zinc. - Google Patents
Tratamientos oncológicos con agentes de zinc.Info
- Publication number
- MX2020013883A MX2020013883A MX2020013883A MX2020013883A MX2020013883A MX 2020013883 A MX2020013883 A MX 2020013883A MX 2020013883 A MX2020013883 A MX 2020013883A MX 2020013883 A MX2020013883 A MX 2020013883A MX 2020013883 A MX2020013883 A MX 2020013883A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- agent
- treating
- cancer patient
- oncology treatments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención se refiere a métodos para tratar a un paciente con cáncer que comprenden la administración de un agente de Zn(II) o una combinación de agente de Zn(II)/agente inmuno-oncológico para proporcionar un beneficio terapéutico al paciente con cáncer. Los métodos son útiles para tratar un amplio espectro de cánceres humanos, incluyendo tumores sólidos y células cancerosas de origen sanguíneo. En modalidades particulares, los métodos de tratamiento están dirigidos a tipos de cáncer caracterizados por mutaciones de inestabilidad genética.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201805412TA SG10201805412TA (en) | 2018-06-22 | 2018-06-22 | Zinc agents for monotherapy and combination therapy oncology treatments |
SG10201811577TA SG10201811577TA (en) | 2018-12-24 | 2018-12-24 | Oncology treatments using zinc agents |
PCT/SG2019/050308 WO2019245458A1 (en) | 2018-06-22 | 2019-06-21 | Oncology treatments using zinc agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020013883A true MX2020013883A (es) | 2021-05-27 |
Family
ID=67108114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013883A MX2020013883A (es) | 2018-06-22 | 2019-06-21 | Tratamientos oncológicos con agentes de zinc. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210128609A1 (es) |
EP (1) | EP3810154A1 (es) |
JP (1) | JP2021527707A (es) |
KR (1) | KR20210024065A (es) |
CN (1) | CN112584842A (es) |
AU (1) | AU2019290345A1 (es) |
CA (1) | CA3104612A1 (es) |
MX (1) | MX2020013883A (es) |
SG (1) | SG11202012373YA (es) |
WO (1) | WO2019245458A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
JP2024510327A (ja) * | 2021-03-18 | 2024-03-06 | ジロニックス・ピーティーイー.リミテッド | 医薬ポリマーコンジュゲート |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008141110A2 (en) | 2007-05-09 | 2008-11-20 | Nitto Denko Corporation | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
WO2014155142A1 (en) | 2013-03-28 | 2014-10-02 | Bbs Nanotechnology Ltd. | Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it |
EP2989115A4 (en) | 2013-04-26 | 2017-01-11 | Nitto Denko Corporation | A large scale process for preparing poly (glutamyl-glutamate) conjugates |
AU2017312121A1 (en) * | 2016-08-19 | 2019-03-21 | Brooklyn Immunotherapeutics Llc | Uses of PD-1/PD-L1 inhibitors and/or CTLA-4 inhibitors with a biologic containing multiple cytokine components to treat cancer |
SG10201609131YA (en) * | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
-
2019
- 2019-06-21 CN CN201980054635.0A patent/CN112584842A/zh active Pending
- 2019-06-21 US US17/252,834 patent/US20210128609A1/en active Pending
- 2019-06-21 WO PCT/SG2019/050308 patent/WO2019245458A1/en unknown
- 2019-06-21 EP EP19734531.7A patent/EP3810154A1/en active Pending
- 2019-06-21 AU AU2019290345A patent/AU2019290345A1/en active Pending
- 2019-06-21 SG SG11202012373YA patent/SG11202012373YA/en unknown
- 2019-06-21 JP JP2020571709A patent/JP2021527707A/ja active Pending
- 2019-06-21 CA CA3104612A patent/CA3104612A1/en active Pending
- 2019-06-21 MX MX2020013883A patent/MX2020013883A/es unknown
- 2019-06-21 KR KR1020217002195A patent/KR20210024065A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210024065A (ko) | 2021-03-04 |
US20210128609A1 (en) | 2021-05-06 |
JP2021527707A (ja) | 2021-10-14 |
WO2019245458A1 (en) | 2019-12-26 |
AU2019290345A1 (en) | 2021-01-07 |
CA3104612A1 (en) | 2019-12-26 |
EP3810154A1 (en) | 2021-04-28 |
SG11202012373YA (en) | 2021-01-28 |
CN112584842A (zh) | 2021-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551908A1 (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
EP4324460A3 (en) | Sodium bicarbonate for use in the treatment of gout and related disorders | |
TW201613589A (en) | Combination methods for treating cancers | |
MX2019006331A (es) | Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos. | |
MX2020001727A (es) | Terapia de combinacion. | |
PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
MX2021008972A (es) | Terapia de combinacion de quelante metalico para el tratamiento del cancer. | |
MX2020013883A (es) | Tratamientos oncológicos con agentes de zinc. | |
MX2022003190A (es) | Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. | |
WO2020005172A3 (en) | Near-infrared (nir) absorbing photosensitizers | |
HK1096023A1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
MX2020004960A (es) | Asociacion de activos para tratar el cancer de prostata. | |
IL177953A0 (en) | Combination therapy including azd2171 and a taxane | |
MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
WO2008144659A3 (en) | Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers | |
BRPI0412408A (pt) | métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste | |
MX2019014842A (es) | Uso de una combinación de ivosidenib y radiación para tratar gliomas. | |
MX2023005314A (es) | Composiciones de nanoparticulas para tratamiento de cancer. | |
MX2019014934A (es) | Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas. | |
NZ742470A (en) | Combination therapy for cancer | |
MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. |